Triple negative breast cancer (TNBC) has an aggressive clinical behaviour, with a poorer prognosis compared to other subtypes. Recently, tumor-infiltrating lymphocytes (TILs) have been proposed as a predictive biomarker for a better clinical outcome and pathological response (pR) after neoadjuvant chemotherapy (NACT) in TNBC. These data confirm the role of the immune system in the neoplastic progression and in the response to therapy. We performed a retrospective analysis of 54 pre-NACT biopsies of TNBC and compared both the percentage of stromal TILs and the degree of PD-L1 expression with the extent of pR to standard NACT. A pathological complete response (pCR) was achieved in 35% of cases. Univariate analysis showed (i) a significant association between PD-L1 expression in ≥25% of neoplastic cells and the achievement of a pCR (p= 0.024); (ii) a significantly higher frequency of pCR in cases showing ≥50% stromal TILs (p< 0.001). However in the multivariate analysis only PD-L1 expression on tumor cells remained significantly associated with pCR (OR = 1,13; 95% CI 1,01-1,27), suggesting that the expression of this biomarker could be associated with a subpopulation of TNBC more likely to respond to chemotherapy. These data need to be confirmed by larger studies.

PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy? / Cerbelli, Bruna; Pernazza, Angelina; Botticelli, Andrea; Fortunato, Lucio; Monti, Massimo; Sciattella, Paolo; Campagna, Domenico; Mazzuca, Federica; Mauri, Maria; Naso, Giuseppe; Marchetti, Paolo; d'Amati, Giulia; Costarelli, Leopoldo. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - ELETTRONICO. - 2017:suppl_5(2017). [10.1155/2017/1750925]

PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy?

Cerbelli, Bruna
Primo
Investigation
;
Pernazza, Angelina
Secondo
Investigation
;
Botticelli, Andrea
Conceptualization
;
Monti, Massimo
Writing – Review & Editing
;
Sciattella, Paolo
Membro del Collaboration Group
;
Campagna, Domenico
Membro del Collaboration Group
;
Mazzuca, Federica
Membro del Collaboration Group
;
Naso, Giuseppe
Writing – Review & Editing
;
Marchetti, Paolo
Conceptualization
;
d'Amati, Giulia
Penultimo
Writing – Original Draft Preparation
;
2017

Abstract

Triple negative breast cancer (TNBC) has an aggressive clinical behaviour, with a poorer prognosis compared to other subtypes. Recently, tumor-infiltrating lymphocytes (TILs) have been proposed as a predictive biomarker for a better clinical outcome and pathological response (pR) after neoadjuvant chemotherapy (NACT) in TNBC. These data confirm the role of the immune system in the neoplastic progression and in the response to therapy. We performed a retrospective analysis of 54 pre-NACT biopsies of TNBC and compared both the percentage of stromal TILs and the degree of PD-L1 expression with the extent of pR to standard NACT. A pathological complete response (pCR) was achieved in 35% of cases. Univariate analysis showed (i) a significant association between PD-L1 expression in ≥25% of neoplastic cells and the achievement of a pCR (p= 0.024); (ii) a significantly higher frequency of pCR in cases showing ≥50% stromal TILs (p< 0.001). However in the multivariate analysis only PD-L1 expression on tumor cells remained significantly associated with pCR (OR = 1,13; 95% CI 1,01-1,27), suggesting that the expression of this biomarker could be associated with a subpopulation of TNBC more likely to respond to chemotherapy. These data need to be confirmed by larger studies.
2017
PD-L1; triple negative; breast cancer
01 Pubblicazione su rivista::01a Articolo in rivista
PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy? / Cerbelli, Bruna; Pernazza, Angelina; Botticelli, Andrea; Fortunato, Lucio; Monti, Massimo; Sciattella, Paolo; Campagna, Domenico; Mazzuca, Federica; Mauri, Maria; Naso, Giuseppe; Marchetti, Paolo; d'Amati, Giulia; Costarelli, Leopoldo. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - ELETTRONICO. - 2017:suppl_5(2017). [10.1155/2017/1750925]
File allegati a questo prodotto
File Dimensione Formato  
Cerbelli_PD-L1 Expression_2017.pdf

accesso aperto

Note: https://www.hindawi.com/journals/bmri/2017/1750925/
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.11 MB
Formato Adobe PDF
2.11 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1083017
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 43
social impact